 "Strides Shasun receives DCGI's nod for hepatitis C drug sofosbuvir")
Strides Shasun Limited (formerly Strides Arcolab Limited) has received approval for manufacturing sofosbuvir 400 mg (the generic version of Gilead’s Sovaldi) from Drug Controller General of India (DCGI).
In September 2014, Strides entered into a licensing agreement with Gilead Sciences Inc to bring hepatitis C cure to 91 developing countries. The product will be marketed under the brand name ‘Virso’ in India and overseas.
“Sofosbuvir is the first-in-class NS5B polymerase inhibitor to be launched in India for hepatitis C treatment and represents a paradigm shift in the existing hepatitis C cure. The high potency, high barrier to resistance, pan genotypic activity, once-daily dosage, good safety profile and the limited drug-drug interactions of sofosbuvir makes it a breakthrough drug in hepatitis C treatment. This drug in combination therapy has shown to have high cure rates of around 90 percent,” said Strides Shasun in a press release on December 21, 2015.
Globally, it is estimated that 170-185 million people (about 3 percent of the world’s population) are chronically infected with hepatitis C virus (HCV). In India alone, it is estimated that 12-18 million patients are infected with hepatitis C, which is several fold greater than those with HIV/AIDS.
In September 2014, Strides entered into a licensing agreement with Gilead Sciences Inc to bring hepatitis C cure to 91 developing countries. The product will be marketed under the brand name ‘Virso’ in India and overseas.
“Sofosbuvir is the first-in-class NS5B polymerase inhibitor to be launched in India for hepatitis C treatment and represents a paradigm shift in the existing hepatitis C cure. The high potency, high barrier to resistance, pan genotypic activity, once-daily dosage, good safety profile and the limited drug-drug interactions of sofosbuvir makes it a breakthrough drug in hepatitis C treatment. This drug in combination therapy has shown to have high cure rates of around 90 percent,” said Strides Shasun in a press release on December 21, 2015.
Globally, it is estimated that 170-185 million people (about 3 percent of the world’s population) are chronically infected with hepatitis C virus (HCV). In India alone, it is estimated that 12-18 million patients are infected with hepatitis C, which is several fold greater than those with HIV/AIDS.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%